News
Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...
Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...
2d
Stocktwits on MSNThis Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point
Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...
Regeneron Court Permits Government to Pursue False Certification Theory - On August 4, the district court in the closely ...
5d
Zacks Investment Research on MSNAmgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season
Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The ...
The competitive landscape of the ARMD market in 2025 is dominated by a few key players and a leading product. Eylea, a therapy for age-related molecular degeneration, is projected to command a ...
CNW/ - (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced its financial results for the quarter ended June 30, ...
Half Year Results/Half Year ReportFormycon confirms full-year guidance following business development in line with plan – working capital raised 13.08.2025 / 06:30 CET/CESTThe issuer is solely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results